Cash, cash, cash. Can't see a CR and associated dilution round these parts! Nice to see in a biotech. Pretty rare. NEU are locked and loaded, ready to fund some trials!
Imagine the income when we have drugs for more than one therapy on the market!! That's if NEU isn't taken out as a massive premium by then...
The only issue is that I can't work out if the profits, or the good in the world that these drugs can/will do, is the added bonus...
Damn I love this company.
Ann: Neuren receives US$100m for expanded DAYBUE agreement, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.11 |
Change
-0.090(0.63%) |
Mkt cap ! $1.750B | |||
| Open | High | Low | Value | Volume |
| $14.23 | $14.71 | $14.01 | $6.213M | 438.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7700 | $14.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.16 | 3278 | 1 |
View Market Depth
| Last trade - 16.16pm 30/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |